After so much effort to bring immunotherapy into HR+/HER2− mBC, KEYNOTE-B49 raises a hard question: is this worth it? A 0.7-month median PFS gain and no demonstrated OS benefit. We need more meaningful returns for our patients. #ESMO26 @myESMO @Larvol @OncoAlert